arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CNBX Pharmaceuticals Inc.

CNBX
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
21 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
54
Health
Fair
Bullish
auto_awesome

Analytical Summary

CNBX Pharmaceuticals Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth N/M
Op. Margin None
ROIC 8.6% ↘
FCF / Share $-0.00 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

21-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-313.98K
↑ +54.8% —
Operating Margin Operating profit as % of sales
-448.3%
↓ -97.4% —
FCF / Share Free cash flow per share
$-0.00
↑ +76.6% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
75
Financial Health ↑
34
Cash Quality ↓
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 21 years · 70 quarters